Research Summary
Dr. Rudek is investigating the pharmacokinetic and pharmacodynamic behavior of anticncer gents and identify determinants that impact on the PK/PD variability of these agents with the hopes of individualizing therapy.
Clinical Trials
Learn more about clinical trials at the Johns Hopkins Kimmel Cancer Center.
Selected Publications
View all on PubMed
Rudek MA, Figg WD, Dyer V, Dahut W, Turner ML, Steinberg SM, Liewehr DJ, Kohler DR, Pluda JM, Reed E. A phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol. 2001;19(2):584-592.
Rudek MA, Zhao M, He P, Hartke C, Gilbert J, Gore SD, Carducci MA, Baker SD. Pharmacokinetics of 5- azacytidine given with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol. 2005;23(17):3906-3911.
Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in cancer patients with HIV/AIDS. Lancet Oncol. 2011;12(9):905-12.
Anders NA, Liu J, Wanjiku T, Giovinazzo H, Zhou J, Vaghasia A, Nelson WG, Yegnasubramanian S*, Rudek MA*. Simultaneous quantitative determination of 5-aza-2′-deoxycytidine genomic incorporation and DNA demethylation by liquid chromatography tandem mass spectrometry as exposure-response measures of nucleoside analog DNA methyltransferase inhibitors. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1022:38-45.
Mansfield AS*, Rudek MA*, Vulih D, Smith GL, Harris PJ, Ivy SP. The effect of hepatic impairment on outcomes in phase 1 clinical trials in cancer subjects. Clin Cancer Res. 2016 May 17. doi:10.1158/1078-0432.CCR-16-0449.